筛查效能

在11-13周筛查的目的是筛选出那部分有可能通过预防性使用阿司匹林减少（超过60%）发生未足月子痫前期的高风险孕妇。

在筛查阳性率10%的情况下，联合母体因素、平均动脉压、子宫动脉搏动指数、PLGF，可以预测90%的早发型子痫前期（<34周)，75%的未足月子痫前期（<37 周）及45%的足月子痫前期（≥37 周)。

• 增加PAPP-A及sFLT-1并不能提高筛查效果。

筛选可能通过阿司匹林预防子痫前期发生的高风险孕妇，传统方法是基于孕妇病史。英国国家健康和临床质量管理中心（NICE）推荐基于孕妇特征及病史的10项高危因素来筛选子痫前期的高危人群，但这仅能筛出40% 的未足月子痫前期及35%的足月子痫前期。美国妇产科医师学会（ACOG）对于有≥2次子痫前期妊娠史或曾经有过小于34周分娩的子痫前期病史的孕妇推荐使用阿司匹林，这种方法可以筛选出5%的未足月子痫前期及2%的足月子痫前期。

1. O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Am J Obstet Gynecol 2016;214:103.e1-103.e12.
2. National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: RCOG Press, 2010.
3. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122: 1122-31.
4. O’ Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, Carbone IF, Dutemeyer V, Fiolna M, Frick A, Karagiotis N, Mastrodima S, de Paco Matallana C, Papaioannou G, Pazos A, Plasencia W, Nicolaides KH. Multicenter screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation: comparison to NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol 2017; 49: 756-60.